Just topped up significantly more at .215c, trails don't progress to phase III without substantial results in phase 1 or 2 warranting further experiments and analysis. Given the interim results have already been collected for analysis indicates to me the patients are doing well and treatments are effectively working ahead of schedule without any negative impacts. Not to mention the old saying, be greedy when others are fearful.
Nina has been very positive and confident with phase III thus far and I believe the interim results will further reinforce this confidence.
IMO, this is being surpressed for accumulation as it did when the Advanz ann occured and the price was pushed to 11c only to shoot up to mid 20s immediately after. The market is sleeping on this one, and the overall red on the markets today may be playing a factor today for this ann, along with oppies holders who may be looking to convert with the liquidity.
dyor, gltah
Interim Analyses of Clinical Trials, page-58
-
- There are more pages in this discussion • 128 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
55.0¢ |
Change
-0.060(9.84%) |
Mkt cap ! $302.3M | |||
| Open | High | Low | Value | Volume |
| 60.5¢ | 61.0¢ | 55.0¢ | $2.309M | 4.010M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 137019 | 55.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 55.5¢ | 22500 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| DXB (ASX) Chart |